Pharmaceuticals

Seelos Therapeutics

Seelos Therapeutics Signs Agreement with US Army to Evaluate SLS-002 for PTSD Treatment

Seelos Therapeutics Inc announces layoffs

Akanda

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Agape ATP

Co-Diagnostics

NewGenIvf

Netcapital

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

SEELQ

SEEL

ARKG

LABU

Seaport Therapeutics (SPTX), a Boston-based biotech, has increased its IPO size to 14.16 million shares, priced at $18.00, raising $254.88 million. The shares will begin trading on NASDAQ on May 1, 2026. The company plans to use the proceeds for Phase 2 clinical trials of its drugs for major depression. At pricing, Seaport Therapeutics has a market cap of $954.5 million. Goldman Sachs and others are the joint book-runners for the IPO.

IPO Scoop

SEELOS THERAPEUTICS INC

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Goldman Sachs

JPMorgan Chase

Citigroup

Stifel Financial

Nasdaq

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range

588130

512170

512290

516500

On April 29, 2026, Avalyn Pharma Inc. announced the pricing of its upsized initial public offering, consisting of 16,666,667 shares priced at $18.00 each, aiming for gross proceeds of approximately $300 million. The company is offering all shares and has granted underwriters a 30-day option to purchase an additional 2,500,000 shares at the IPO price, net of discounts and commissions.

Fidelity

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP CSI Medical Service ETF

VG Health

Guotai CSI Bio-medicine ETF

iShares US Pharma

ChinaAMC CSI Biotechnology Theme ETF

Morgan Stanley

Jefferies Financial

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Avalyn Announces Pricing of Upsized Initial Public Offering

426CVR015TMP

COEP

NBSE.ESC

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Hepion Pharmaceuticals, Inc.

Coeptis Therapeutics

ESC NEUBASE THERAPEUTI

Seaport ENT

Seaport and Hemab target $180m IPOs as biotech listings accumulate

April 27 (Reuters) - Drug developers Seaport Therapeutics and Hemab Therapeutics launched their U.S. initial public offerings on Monday, seeking to capitalize on a growing investor appetite for new listings. The U.S. IPO market has regained momentum this month, as improving risk appetite and stronger investor sentiment encourage companies across sectors to pursue listings, despite the risks a

Seaport, Hemab launch US IPOs as biotech listings gather momentum

Seaport Therapeutics, a Boston-based biotech firm focused on neuropsychiatric therapies, has announced terms for its $201 million IPO, planning to offer 11.8 million shares priced between $16 and $18. The company, founded in 2024, is developing oral therapies for conditions like depression and anxiety using its proprietary Glyph platform. Its lead programs include GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Seaport plans to list on Nasdaq under the symbol SPTX, with pricing expected the week of April 27, 2026.

RenaissanceCapital

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week

Seelos Therapeutics(SEEL.US)

The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range

Avalyn Announces Pricing of Upsized Initial Public Offering

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Seaport, Hemab launch US IPOs as biotech listings gather momentum

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week